A patented holistic solution to joint health
BioCell Collagen® is a patented ingredient which offers an ideal approach to complex joint problem. It is not an artificial combination but a naturally-occurring matrix of hydrolyzed collagen type II and low molecular weight (LMW) hyaluronic acid (HA) and chondroitin sulfate. Due to a proprietary manufacturing process, these essential molecules are highly bioavailable and, once ingested, appear to be biologically active for cartilage regeneration. Its safety and efficacy has been proven by multiple human clinical trials and also by safe use of billions of doses by the consumer worldwide.
A synergy of hydrolyzed collagen type II, HA, and chondroitin sulfate
BioCell Collagen® is a holistic joint solution because its composition mirrors that of human cartilage. Intake of both collagen and GAGs would be more desirable for effective and long-term joint health than a partial approach of ingesting either collagen (e.g., undenatured/unhydrolyzed collagen) or GAGs (e.g., glucosamine and/or chondroitin sulfate) only. In addition, a patented process developed by BioCell Technology makes these cartilage molecules remarkably bioavailable for fast and effective absorption, as shown in human bioavailability studies.
More importantly, hydrolyzed collagen type II, but not undenatured/unhydrolyzed collagen, has been shown to stimulate the synthesis of novel collagen type II, suggesting potential cartilage regeneration. Furthermore, collagen-derived peptides which are present in the bloodstream appear to protect the cartilage-forming chondrocytes, thereby preventing the thinning of cartilage.
Strong scientific substantiation by multiple human clinical trials
Over the last decade, three human clinical trials demonstrated the safety and efficacy of BioCell Collagen® in improving joint discomfort. A recent double-blinded, placebo-controlled clinical trial, the outcome of which was published in the prestigious Journal of Agricultural and Food Chemistry, enrolled 80 subjects suffering from a progressed stage of joint discomfort and demonstrated that 71% of the subjects who ingested 2 g daily of BioCell Collagen® experienced at least 30% reduction of discomfort while 30% in the placebo had a similar effect. With stricter criteria of minimum 40% reduction of joint discomfort, 51% in the BioCell Collagen group enjoyed the benefit whereas only 12% in the placebo did so. This outcome has confirmed a remarkable efficacy and safety of BioCell Collagen®, which was also observed in earlier clinical trials.